Infection‑Linked Cancers: Five Germs Behind One‑Eighth of Global Cases

When you hear the word “cancer,” you probably think of smoking, alcohol, processed foods or polluted air. It’s easy to overlook another, less obvious culprit: infections. A fresh analysis from the International Agency for Research on Cancer (IARC), the WHO’s cancer‑research arm, says that in 2024 roughly 2.3 million new cancer cases – about one in eight worldwide – were linked to infectious agents.

The picture isn’t uniform across the globe. Low‑ and middle‑income nations bore about 77 % of those infection‑related cancers, highlighting stark inequities in prevention and treatment. Still, the same data point to a silver lining: if we can curb the five main germs, we could slash a sizable slice of the cancer burden.

So, which microbes are we talking about? The study, published in The Lancet Oncology, flags Helicobacter pylori, human papillomavirus (HPV), hepatitis B virus (HBV), hepatitis C virus (HCV) and Epstein‑Barr virus (EBV). They’re very different – some are bacteria, others viruses – yet they share a sneaky trait: when they stick around for years, they can nudge healthy cells toward a malignant destiny.

Let’s break down how each one does its thing, and what we can actually do about it.

1. Helicobacter pylori – the stomach‑settling bacterium. Most people catch it in childhood, often without any drama. Over time, however, chronic gastritis can set the stage for stomach cancer or even a type of non‑Hodgkin lymphoma. In 2024 the bug was blamed for an estimated 760,000 cancers – roughly 4 % of all new cases. The good news? It’s treatable. A combination of antibiotics and acid‑reducing meds can clear the infection, and research suggests that doing so could cut stomach cancer rates by about a third.

There’s no approved vaccine yet, so detection and eradication remain our best bet.

2. Human papillomavirus (HPV) – the virus that loves skin‑to‑skin contact. Most infections are harmless and disappear on their own, but a handful of high‑risk strains can linger and eventually cause cancer. HPV is the leading cause of cervical cancer and also plays a role in cancers of the anus, penis, vagina, vulva and the throat. The Lancet report tied about 750,000 new cancers in 2024 to HPV – again around 4 % of the global total.

Vaccination is a game‑changer. Routine HPV shots for pre‑teens and young adults have already driven down infection rates and precancerous lesions in countries with robust programs. Pair that with regular cervical screening, and you have a powerful two‑pronged defense.

3. Hepatitis B virus (HBV) – the liver‑targeting virus. Some people clear it quickly; others become chronic carriers, especially if infected early in life. Persistent inflammation can scar the liver (cirrhosis) and eventually spark liver cancer. In 2024 HBV was linked to about 360,000 cancers – roughly 2 % of all new diagnoses.

The cornerstone of prevention is a safe, effective vaccine, which the WHO recommends for all infants. For those already infected, antiviral therapy can keep the virus in check and reduce cancer risk.

4. Hepatitis C virus (HCV) – another liver invader, but unlike HBV it’s an RNA virus and spreads mainly through blood. Chronic HCV infection leads to similar outcomes: cirrhosis and liver cancer. It accounted for a comparable share of infection‑related cancers as HBV in the study.

Direct‑acting antivirals (DAAs) have revolutionized treatment – a 12‑week course can cure most patients, dramatically lowering their cancer risk. The challenge remains identifying people who are unaware they carry the virus.

5. Epstein‑Barr virus (EBV) – the infamous culprit behind mononucleosis. Most adults have been infected at some point, yet the virus can linger in B‑cells and, under certain conditions, drive cancers such as nasopharyngeal carcinoma, certain stomach cancers and some lymphomas.

There’s no vaccine for EBV yet, and treatment focuses on managing the cancers that arise. Research into EBV‑targeted therapies is ongoing.

Why does an infection sometimes become cancerous? It’s rarely a straight line. Persistent infection can keep the immune system in a state of chronic inflammation, damaging DNA and encouraging rogue cell growth. Some viruses also insert their genetic material into host cells, hijacking the normal controls on cell division.

Crucially, most people who harbor these microbes never develop cancer. The risk is a tangled mix of how long the infection lasts, the host’s immune response, genetics, lifestyle factors and environmental exposures.

What does this mean for public health? Plenty. The analysis underscores that vaccines, early screening and timely treatment are not just medical niceties – they’re potent tools to shave years of suffering off the global cancer tally. Yet the reach of these interventions is uneven. High‑income countries often enjoy universal HPV vaccination and routine hepatitis screening, while many low‑resource settings struggle with basic diagnostics.

Bridging that gap will require political will, investment in health infrastructure and community education. When we succeed, the payoff is huge: fewer people losing their lives to cancers that, in many cases, are preventable.

In short, the battle against cancer isn’t just about cigarettes and junk food; it’s also about getting a grip on a handful of sneaky infections. By vaccinating, screening, and treating wisely, we can turn the tide against a silent, yet sizeable, driver of the global cancer crisis.